Ignite Creation Date:
2025-12-24 @ 11:07 PM
Ignite Modification Date:
2025-12-25 @ 8:39 PM
Study NCT ID:
NCT02320669
Status:
COMPLETED
Last Update Posted:
2024-04-09
First Post:
2014-12-05
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass
Sponsor:
Seattle Children's Hospital
Organization:
Study Overview
Official Title:
Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass
Status:
COMPLETED
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TRICC-2
Brief Summary:
This is a study to determine the safety and efficacy of liothyronine sodium/triiodothyronine (Triostat), a synthetic thyroid hormone, when given to infants with congenital heart disease during cardiopulmonary bypass surgery. Funding Source - FDA OOPD.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| R01FD004362-01A2 | FDA | None | https://reporter.nih.gov/quic… | View |